Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease - Test2 - elhamkhani - TriplyDB

Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease

Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease

http://www.wikidata.org/entity/Q24617270

about

Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition Advances in the treatment of rheumatoid arthritis.Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis Update on Janus kinase antagonists in inflammatory bowel disease.Structural basis of recognition of interferon-α receptor by tyrosine kinase 2 The arrival of JAK inhibitors: advancing the treatment of immune and hematologic disorders.STAT3 induction of miR-146b forms a feedback loop to inhibit the NF-κB to IL-6 signaling axis and STAT3-driven cancer phenotypes Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis.Gene mutations and molecularly targeted therapies in acute myeloid leukemia.Effects of sulfasalazine and tofacitinib on the protein profile of articular chondrocytes.Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia.What is the future of targeted therapy in rheumatology: biologics or small molecules?Regulation of cell transformation by Rb-controlled redox homeostasis.Improvement of spontaneous locomotor activity with JAK inhibition by JTE-052 in rat adjuvant-induced arthritis.Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy Network pharmacology of JAK inhibitors MLS-2384, a new 6-bromoindirubin derivative with dual JAK/Src kinase inhibitory activity, suppresses growth of diverse cancer cells Janus kinase 1/3 signaling pathways are key initiators of TH2 differentiation and lung allergic responses.The Innovative Medicines Initiative moves translational immunology forward.Tofacitinib: a review of its use in adult patients with rheumatoid arthritis.New targeting strategies in drug therapy of inflammatory bowel disease: mechanistic approaches and opportunities.Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases.Kinase inhibitors: the next generation of therapies in the treatment of rheumatoid arthritis.Novel treatments with small molecules in psoriatic arthritis.Tofacitinib for the treatment of moderate-to-severe psoriasis.Psoriatic arthritis: latest treatments and their place in therapy.Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside.Oxindole-based SYK and JAK3 dual inhibitors for rheumatoid arthritis: designing, synthesis and biological evaluation.Design, synthesis, and evaluation of the anticancer activity of 2-amino-aryl-7-aryl-benzoxazole compounds.The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease.Beyond TNF Inhibitors: New Pathways and Emerging Treatments for Psoriatic Arthritis.Quinoxaline-Based Scaffolds Targeting Tyrosine Kinases and Their Potential Anticancer Activity.Role of interleukin-6 in cancer progression and therapeutic resistance.Kinases as Novel Therapeutic Targets in Asthma and Chronic Obstructive Pulmonary Disease.Effects of tofacitinib on nucleic acid metabolism in human articular chondrocytes.Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities.Tumor Necrosis Factor-Alpha and Pregnancy: Focus on Biologics. An Updated and Comprehensive Review.Overcoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitors Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration.Sorafenib analogue SC-60 induces apoptosis through the SHP-1/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells.

P2860

Q27683852-EB6AB749-622D-4604-BEFA-7D8CF96DE342 Q27691822-1C08AD76-0948-4F33-AD0E-BD1A7B24D71B Q33429617-EF6F9B18-E4D3-4D26-86EB-00CB7DBDED26 Q34030650-80AA7886-FE01-4A74-B53F-9F809675575E Q34165581-6D38D4C1-9BE7-4C33-96E7-6A6AC8B6A997 Q34349150-507FE5DA-87A4-45B2-B526-3F3820D006D3 Q34518047-5142E511-64FD-41D9-AE25-61EC9443897D Q34529981-D0826754-9962-4186-A249-4E031BEDF41E Q34647741-8CAAF92D-864A-4A68-BC47-A4A806E9CD7C Q35064975-655CF750-96BC-4E0D-A3D3-73A85BA98697 Q35072638-EC32E5AE-5C84-4FEB-AC57-2B72F90A5B14 Q35118364-02457B96-F3BD-4C73-AAA9-7F2CD8044A75 Q35206258-003683C0-F18D-4B86-B0F5-2BA02DF27D96 Q35834909-29634365-A811-4661-9FB1-4AD15235688C Q36723728-CCB104F9-6625-449A-BEA4-AC5C4235141B Q37258632-62AFDE7E-624B-4DF3-9676-A6411CBA7AA9 Q37591464-4E20C58C-5F7C-45D4-AD96-8A1D6AD0B022 Q37678487-893ECF9F-0EAA-41BC-9BCC-19AAFBAC8D81 Q38093624-DA70D21F-8868-401E-BD82-9DA4B5A4C671 Q38110227-838EA92D-C36E-4516-89D1-19282784EC65 Q38110619-EF3B1CAA-1A53-40BF-9493-5C7189D8F6A9 Q38169198-B8524559-129E-4383-874C-54FB431CF4A9 Q38181610-E654AACF-174A-45D8-852C-9E7F1767A620 Q38229893-8DF5E567-ED0A-4601-8A76-C0C6FAB655A0 Q38349779-CB8F9E1C-B564-4E8A-8890-0B23A6AD9756 Q38542095-E45B60B5-6FB8-46AB-ABA3-D9A7C360862F Q38543700-22BEF70C-8741-401F-A65E-FEE42B6C2F8B Q38655324-5185709A-210F-42A2-9B19-A530497F3145 Q38702290-F737257E-E85B-490B-8058-0FA2E407FDB9 Q38761961-40436C08-8727-4C4A-982F-0EFAA7DD24E6 Q38766379-AD295C4D-527A-4493-802E-1CDE701DE427 Q38803278-0CBB9B84-930B-47C2-9EEA-99A850E51E41 Q38853625-36DD64E7-0063-43F6-B06D-A184A32DEAF8 Q38882099-7298F1AE-B3BE-4E69-852D-0E1AD2FBFC81 Q38929939-65894DC6-BA95-4D83-A0EA-B29292E9FB7F Q38953721-37C1C78E-0FE7-4548-B0FD-D2A777A85167 Q39039141-37D7063D-F04E-4A74-B0A2-843755261B88 Q39096636-439B5385-722E-489F-BBF8-C857DAABD8A7 Q40768273-433D83DA-6AAF-4E7A-84FA-44755CF50C8E Q41127816-704698E5-0C34-47BB-A321-8A1BFAB5C2EE

P2860

Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease

http://www.wikidata.org/entity/Q24617270

description

2012 nî lūn-bûn

@nan

2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease

@ast

Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease

@en

Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease

@nl

type

label

Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease

@ast

Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease

@en

Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease

@nl

prefLabel

Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease

@ast

Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease

@en

Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease

@nl

P1433

Q24617270-CB02EA75-11CF-4158-A125-ECED00C7C2C0

P1476

Q24617270-422F02C9-E0EE-4D01-8E92-3D5657AC845C

P2093

Q24617270-070CAFEB-02FA-431D-93ED-738AD5F12C90

Q24617270-126B31B4-F3BE-4763-AC13-F8FA69B5D508

Q24617270-293CF5AE-0AD5-4EC5-B8FC-8A875A79FD21

Q24617270-9B922885-656E-47D1-B53B-7CE10CF14EA9

Q24617270-D487D999-5342-4509-9CAE-293EDFE59066

P2860

Q24617270-037981E1-5DAA-46A7-B9CE-8B6825C08E5A

Q24617270-04BD12B7-EF63-4BC9-8911-7E01C1505B4A

Q24617270-07A1443D-F480-4A07-9EE9-B614BE0D576C

Q24617270-0DE60B06-7F96-4506-B3D8-0494CB4E47C4

Q24617270-1321A5D9-DEB6-40A1-8B83-B01218059B33

Q24617270-17831BA9-29FC-4E1E-BE15-ECEEA3980606

Q24617270-1B9613F7-D8CF-4C46-8F54-DF2833266BC4

Q24617270-2144201E-7C7B-44B2-8F23-8B2A8B917FA7

Q24617270-278E08FA-39CE-4740-A3B5-F9D9A459E2D4

Q24617270-28D8252E-3DC8-40C9-A0E6-B9860E0FA402

P304

Q24617270-68A84F71-4920-45E1-B5E8-CCBB950C6D44

P31

Q24617270-CFBDFDB2-A10B-413B-8D4C-F1D327680BC7

P356

Q24617270-C6D41328-E0DD-4193-B033-25371D14BCCF

P407

Q24617270-A4C41A77-6C75-400E-B3F8-C59CA56F03E8

P433

Q24617270-343595B5-3ED3-4EE9-8914-9D6AC955D349

P478

Q24617270-7840B34B-B536-4205-B247-021980BDC8F1

P577

Q24617270-91AFDC8D-673A-4CB2-A8EB-263BB1C3DA48

P5875

Q24617270-29AB966B-BF9C-41DC-B9DE-7BC403B55BDA

P698

Q24617270-14F8786C-9D7F-49E0-B5BA-82F6E21E687F

P921

Q24617270-658B254B-A7E5-4498-8A9F-870DA69A8731

P932

Q24617270-D61DD5F2-ADDF-42CB-ADB1-8797B17EABB8

P356

J.COPH.2012.06.008

P1433

Current Opinion in Pharmacology

P1476

Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease

@en

P2093

Alexander Kotlyar

http://www.w3.org/2001/XMLSchema#string

Apostolos Kontzias

http://www.w3.org/2001/XMLSchema#string

Arian Laurence

http://www.w3.org/2001/XMLSchema#string

John J O'Shea

http://www.w3.org/2001/XMLSchema#string

Paul Changelian

http://www.w3.org/2001/XMLSchema#string

P2860

Janus kinases in immune cell signaling

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins

A protein tyrosine kinase in the interferon alpha/beta signaling pathway

A quantitative analysis of kinase inhibitor selectivity

Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)

STATs in cancer inflammation and immunity: a leading role for STAT3

P304

464-70

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.COPH.2012.06.008

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2012-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

229435230

http://www.w3.org/2001/XMLSchema#string

P698

22819198

http://www.w3.org/2001/XMLSchema#string

P921

P932

3419278

http://www.w3.org/2001/XMLSchema#string